Aripiprazole-d₈

Aripiprazole-d₈ is intended for use as an internal standard for the quantification of aripiprazole (Item No. 19989) by GC- or LC-MS. Aripiprazole is an atypical antipsychotic.¹ It is a partial agonist at dopamine D₂, D_2L, and D₃ receptors (K_is = 3.3, 0.74, 9.7 nM, respectively), a partial agonist of the serotonin (5-HT) receptor subtype 5-HT_1A (K_i = 5.6 nM), and an inverse agonist of 5-HT_2B receptors (K_i = 0.36 nM). It is functionally selective at the dopamine D₂ receptor with cell-type- and function-selective activities. Aripiprazole inhibits disruptions in prepulse inhibition induced by phencyclidine in mice when administered at doses of 5 and 10 mg/kg.² Formulations containing aripiprazole have been used in the treatment of schizophrenia, bipolar mania or mixed episodes, and Tourette’s disorder.

WARNING This product is not for human or veterinary use.

1. Shapiro, D.A., Renock, S., Arrington, E., et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28(8), 1400-1411 (2003).

2. Fejgin, K., Safonov, S., Pålsson, E., et al. The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice. Psychopharmacology (Berl.) 191(2), 377-385 (2007).